2025-03-26 12:13:23
Latest Post
Gujarat Ambuja Exports Ltd commences commercial production of Greenfield 1200 TPD Maize Processing unit
Wardwizard Promoters take decisive action with Significant Fund Infusion
EaseMyTrip signs MoU with Tourism New Zealand to strengthen travel ties and enhance Indian tourist arrivals
Welspun Corp Limited increases stake in Welspun Specialty Solutions Ltd
Rulka Electricals Secures 21 New Work Orders totaling Rs 12.36 Crore in March 2025
Stock Report
Nath Bio-Genes India Ltd Q4 FY24 consolidated profit at Rs. 2.61 crore
Posted On : 2024-05-09 08:23:58( TIMEZONE : IST )
Nath Bio-Genes (India) Limited has reported Consolidated financial results for the period ended March 31, 2024.
Financial Results (Q4 FY2024) - QoQ Comparison
The company has reported total income of Rs. 43.0380 crores during the period ended March 31, 2024 as compared to Rs. 31.7376 crores during the period ended December 31, 2023.
The company has posted net profit / (loss) of Rs. 2.6187 crores for the period ended March 31, 2024 as against net profit / (loss) of Rs. 3.8195 crores for the period ended December 31, 2023.
The company has reported EPS of Rs. 1.87 for the period ended March 31, 2024 as compared to Rs. 2.02 for the period ended December 31, 2023.
| Financials | Q4 FY2024 | Q3 FY2024 | % Change |
| Total Income | ₹ 43.0380 crs | ₹31.7376 crs |  35.61% |
| Net Profit | ₹2.6187 crs | ₹3.8195 crs |  -31.44% |
| EPS | ₹1.87 | ₹2.02 | -7.43% |
Financial Results (Q4 FY2024) - YoY Comparison
The company has reported total income of Rs. 43.0380 crores during the period ended March 31, 2024 as compared to Rs.44.9875 crores during the period ended March 31, 2023.
The company has posted net profit / (loss) of Rs.2.6187 crores for the period ended March 31, 2024 as against net profit / (loss) of Rs.1.4369 crores for the period ended March 31, 2023.
The company has reported EPS of Rs.1.87 for the period ended March 31, 2024 as compared to Rs.0.77 for the period ended March 31, 2023.
| Financials | Q4 FY2024 | Q4 FY2023 | % Change |
| Total Income | ₹ 43.0380 crs | ₹44.9875 crs | -4.33% |
| Net Profit | ₹2.6187 crs | ₹1.4369 crs | 82.25% |
| EPS | ₹1.87 | ₹0.77 | 142.86% |
Financial Results (Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.332.6249 crores during the Financial Year ended March 31, 2024 as compared to Rs.301.3637 crores during the Financial Year ended March 31, 2023.
The company has posted net profit / (loss) of Rs.39.6185 crores for the Financial Year ended March 31, 2024 as against net profit / (loss) of Rs.35.0114 crores for the Financial Year ended March 31, 2023.
The company has reported EPS of Rs.21.34 for the Financial Year ended March 31, 2024 as compared to Rs.18.44 for the Financial Year ended March 31, 2023.
| Financials | Year Ended FY2024 | Year Ended FY2023 | % Change |
| Total Income | ₹332.6249 crs | ₹301.3637 crs | 10.37% |
| Net Profit | ₹39.6185 crs | ₹35.0114 crs | 13.16% |
| EPS | ₹21.34 | ₹18.44 | 15.73% |
Shares of Nath Bio-Genes (India) Limited was last trading in BSE at Rs. 204.30 as compared to the previous close of Rs. 198.65. The total number of shares traded during the day was 7617 in over 191 trades.
The stock hit an intraday high of Rs. 204.95 and intraday low of 198.75. The net turnover during the day was Rs. 1540330.00.
